This legislation would end taxpayer support of any research using fetal tissue obtained from an abortion as well as the solicitation of such tissue. It would also close any loopholes in the law allowing for the use of body parts obtained via abortion in federally funded research projects.
End federal taxpayer support for research using fetal tissue obtained from abortions, prohibit solicitation of such tissue, and close loopholes allowing aborted fetal tissue in federally funded research.
Occurrences
Evidence
unverified · Source version 29624 · locator unknown
AP reported that the Trump administration announced human fetal tissue derived from abortions can no longer be used in research funded by the National Institutes of Health. The report said the policy covers all NIH-funded research and reverses Biden-era rollbacks, with NIH Director Jay Bhattacharya saying the agency would seek alternative approaches.
unverified · Source version 61480 · locator unknown
NIH stated that, effective January 22, 2026, NIH funds are not permitted for research using human fetal tissue from elective abortions, and that the policy applies to the NIH intramural program and extramural grants, cooperative agreements, other transaction awards, and R&D contract proposals submitted after the notice.
unverified · Source version 85375 · locator unknown
The NIH Grants Policy Statement says human fetal tissue excludes established human fetal cell lines; its elective-abortion HFT definition also excludes already-established human fetal cell lines, human embryonic stem cells or embryonic cell lines, and transplantation research on HFT for therapeutic purposes. It adds that NIH funds are not permitted for research using HFT from elective abortions effective January 22, 2026.
unverified · Source version 40448 · locator unknown
The statute provides that the Secretary may conduct or support research on transplantation of human fetal tissue for therapeutic purposes, and that human fetal tissue may be used regardless of whether obtained after spontaneous abortion, induced abortion, or stillbirth, subject to consent and compliance requirements.
unverified · Source version 40449 · locator unknown
Current federal law prohibits transfer of human fetal tissue for valuable consideration and prohibits certain directed-donation solicitation or acceptance for transplantation when the tissue is obtained pursuant to an induced abortion. It also prohibits solicitation or acquisition where a pregnancy was deliberately initiated to provide tissue.
unverified · Source version 40450 · locator unknown
NIH's 2021 notice reversed the 2019 requirement that all NIH grant and contract applications proposing use of human fetal tissue from elective abortions be reviewed by an ethics advisory board, while reminding recipients about informed consent and laws against valuable consideration. The page states this notice was rescinded on January 22, 2026 and replaced by NOT-OD-26-028.
unverified · Source version 40451 · locator unknown
The 2019 NIH notice required applicants proposing HFT research to justify use, address procurement and costs, certify compliance with laws, and undergo ethics advisory board review, but it defined exclusions including already-established human fetal cell lines, embryonic stem cells or embryonic cell lines, and transplantation research governed by statute. The notice was rescinded and replaced by NOT-OD-26-028 on January 22, 2026.
unverified · Source version 40452 · locator unknown
AP reported that the Trump administration announced human fetal tissue derived from abortions can no longer be used in NIH-funded research, that the new policy covers all NIH-funded research, and that NIH documents say the policy does not end use of cell lines created years ago from fetal cells.
unverified · Source version 61479 · locator unknown
Full Title To prohibit the Federal Government from conducting or supporting any research involving human fetal tissue that is obtained pursuant to an induced abortion, and to prohibit the solicitation or knowing acquisition, receipt, or acceptance of a donation of such tissue. Sponsors Robert F. Onder, Jr.(MO)
verified · Source version 61480 · locator 1464
Effective the date of this Notice, NIH funds will not be permitted for research using HFT from elective abortions.
unverified · Source version 73419 · locator unknown
The U.S. Department of Health and Human Services (HHS) today ended the permitted use of human fetal tissue from elective abortion in agency-funded research. The National Institutes of Health (NIH), which distributes most HHS medical research funding, is applying this policy across the NIH Intramural Research Program and all NIH-supported extramural research, including grants, cooperative agreements, other transaction awards, and research and development contracts.
unverified · Source version 73421 · locator unknown
42 USC 289g-1: Research on transplantation of fetal tissue Text contains those laws in effect on September 27, 2026. Human fetal tissue may be used in research carried out under paragraph (1) regardless of whether the tissue is obtained pursuant to a spontaneous or induced abortion or pursuant to a stillbirth.
unverified · Source version 85375 · locator unknown
research on transplantation of HFT for therapeutic purposes ... Effective January 22, 2026, NIH funds are not permitted for research using HFT from elective abortions.
unverified · Source version 85377 · locator unknown
That is why I introduced the Protecting Life and Integrity in Research Act ... Now it is time for Congress to finish the job
Assessments
During Onder's current federal House term, NIH adopted a January 22, 2026 policy barring NIH funds for research using human fetal tissue from elective abortions, which delivers the central taxpayer-funding portion of the promise in part. The promise is not fully delivered because the NIH policy preserves exclusions for established fetal cell lines and other categories, federal statute still allows certain fetal-tissue transplantation research, and the evidence does not show a new broad solicitation ban or comprehensive loophole closure attributable to Onder. The completed action was mainly an executive agency action rather than a candidate-sponsored legislative enactment, supporting partial credit rather than full delivery.
Onder took federal office on January 3, 2025, and the cited NIH action occurred on January 22, 2026, so the relevant action falls within his current federal term. The action substantially matches one part of the promise by ending NIH-funded research using fetal tissue obtained from elective abortions. But the claim was broader: it also promised to prohibit solicitation of such tissue and close loopholes allowing aborted fetal tissue in federally funded research, and the provided evidence does not show those additional changes were enacted. Candidate credit is also limited because the documented action was taken by the Trump administration and NIH, with no evidence here that Onder personally sponsored or materially advanced the completed policy change. That supports partial rather than full delivery.